介導(dǎo)白細(xì)胞黏附于血管內(nèi)皮細(xì)胞,首先是中性粒細(xì)胞,隨后是單核(編輯修改稿)
2025-06-22 02:17 本頁面
【文章內(nèi)容簡(jiǎn)介】 月 無合適供者 4療程 HyperCVAD 維持治療 23年或繼續(xù)尋找無血緣供者 初治成人 ALL 31 中國 MM的臨床特點(diǎn)和治療策略 －－單中心 25年回顧性分析 32 Purpose of the study ? Based on the retrospective study of large series in a representative centre, conclude clinical features, response to current treatment and prognosis of multiple myeloma in China。 ? To make new strategy of diagnosis and treatment of multiple myelom according to the advance of basic and clinical research on multiple myeloma, 33 Patients ? 606 MM patients were recorded in BHD, CAMS from 1980 to 2022. ? These patients came from 26 provinces. ? 432 were evaluated for clinical features. ? 257 were evaluated for survival analysis with enough follow up data. ? 195 were treated with conventional therapy over 6 months and evaluated for Tx results. 34 Treatment for MM in BDH ? 1980s1996: conventional CT with MP, M2, COP, VECP. ? 1997: VAD, HDT+ASCT, AlloBMT ? 2022s: Thalidomide 177。MP, VAD/HDDexm 177。 Thalidomide ? 2022: Bortezomib + HDDexm 35 Epidemiology ? Annual incidence: USA: White 4/100,000 Black 10/100,000 Europe: ,000 Asia: ,000 China: no definitive data, probably ,000 ? Age at diagnosis: Western: peak age 6570 y, median age 68y China: peak age 5565 y, median age 55y ? Male to female ratio: :1 36 Age and gender distribution of 432 patients with MM at diagnosis 0 . 9 3 %9 . 2 6 %1 8 . 7 5 %3 2 . 8 7 %2 6 . 8 5 %1 1 . 3 4 % 30y3 0 －4 0 y4 0 －5 0 y5 0 －6 0 y6 0 －7 0 y70ym a l e f e m a l e0 . 0 %2 0 . 0 %4 0 . 0 %6 0 . 0 %8 0 . 0 %PercentStatistics data of Blood Disease Hospital, CAMS 2022, n=432 Male : female＝ ： 1 peak： 55～ 65y， median： 57y 37 Comparison of age at diagnosis BDH ( %) Mayo Clin(%) n＝ 432 n=1027 40 40－ 49 50－ 59 60－ 69 70 38 4 7 . 1 7 %2 1 . 7 %2 1 . 3 8 %5 . 3 5 %4 . 4 % I g Gl i g h t c h a i nI g AI g Do t h e r s monoclonalprotein type in 312 patients A retrospective study of 23 years in BDH,CAMS,2022 39 3 . 0 8 %1 3 . 8 5 %5 . 0 %4 9 . 2 3 %2 8 . 8 5 % s t a g e Is t a g e I I as t a g e I I bs t a g e I I I as t a g e I I I b A retrospective study of 23 years in BDH, CAMS, 2022 The stage of 260 patients at diagnosis 40 Major plication BDH Mayo Clin hyperviscosity ％ %* uricacidmia % % hypercalcemia % % renal failure % % amyloidosis % %* 41 BDH Mayo Clin HB ( g/dL) (255） （ 1025） BMPC ％ (255) %（ 1027） CRP (mg/dl) (121) (285) LDH 76 mol/L ( 181) not given β2 MG( mg/L) (43) (735) Comparison of major hemetological and biochemical values 42 Plain radiograph ?of 281 patients with entire radiographic data , 54 (%) have normal findings, 227 (%) have bone lesions. ? Lytic bone lesions: %(180), esp. skull(%),rib(%), pelvis(%) ? Osteoporosis:%(108) ? Pathologic fractures or pression fracture:%(64) ? Osteosclerosis:%(6) 43 Cytogeics ? Normal karytype:39/70 patients(%) ? Chromos
環(huán)評(píng)公示相關(guān)推薦
鄂ICP備17016276號(hào)-1